You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

Achieving glycemic control is the most important factor for halting disease progression and limiting morbidity and mortality related to type 2 diabetes mellitus (T2DM). Despite availability of effective therapies, most patients do not achieve guideline-recommended glycated hemoglobin (HbA1c) targets. Multiple reasons are linked to this limited success, including clinical inertia, side effects, and patient treatment preferences. New classes of pharmacologic agents are being developed which can overcome many of these barriers while effectively attaining and maintaining glycemic control in T2DM.

Activities

Steering Committee

Steering Committee Chair
  • Michael A. Nauck, MD, PhDMichael A. Nauck, MD, PhD
    Professor of Internal Medicine;
    Head, Specialist Centre for
    Diabetes and Metabolic
    Diseases, Diabetes Centre,
    Bad Lauterberg, Germany
Steering Committee Members
  • Melanie J. Davies, MD, FRCPMelanie J. Davies, MD, FRCP
    Professor of Diabetes Medicine,
    Diabetes Research Unit,
    University of Leicester;
    Honorary Consultant Physician,
    University Hospitals of
    Leicester NHS Trust,
    Leicester, United Kingdom
  • Kamlesh Khunti, MBChB, PhD, MDKamlesh Khunti, MBChB, PhD, MD
    Professor of Primary Care, Diabetes and Vascular Medicine, Department of Health Science, University of Leicester, Leicester, United Kingdom
  • Sten Madsbad, DMScSten Madsbad, DMSc
    Professor; Chief Physician,
    Department of Endocrinology,
    Hvidovre Hospital,
    University of Copenhagen,
    Hvidovre, Denmark
  • Luc Martinez, MDLuc Martinez, MD
    Associate Professor of Family Medicine, University Pierre et Marie Curie; Vice President, French Society of General Medicine, Paris, France
  • Tina Vilsbøll, MD, DMScTina Vilsbøll, MD, DMSc
    Head of Diabetes Research, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.
Supported by an independent educational
sponsorship from
Eli Lilly & Company Global
Polling Question

Multiple weekly GLP-1 RAs are now available for hyperglycemia treatment. Which is the most common reason that you elect to use a particular agent?
Ease of administration
Gastrointestinal tolerability
Effects on body weight
Robustness of glycemic control
Use in patients with renal dysfunction

Related Resources

Downloadable Slide Kits
Clinical Articles
Related Links

Disclosures

Steering Committee
Michael A. Nauck, MD, PhD

Michael A. Nauck, MD, PhD, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Global Services LLC; Lilly Deutschland GmbH; MannKind Corporation; Menarini Group; Merck Sharp & Dohme Corp.; Merck Sharp & Dohme GmbH; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Lilly Deutschland GmbH; Menarini Group; Merck Sharp & Dohme GmbH; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.

Melanie J. Davies, MD, FRCP

Melanie J. Davies, MD, FRCP, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Received grants for clinical research from: GlaxoSmithKline; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Sanofi

Kamlesh Khunti, MBChB, PhD, MD

Kamlesh Khunti, MBChB, PhD, MD, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi

Sten Madsbad, DMSc

Sten Madsbad, DMSc, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Intarcia Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk

Luc Martinez, MD

Luc Martinez, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Mayoly Spindler; Novo Nordisk; Pfizer Inc.; SERVIER

Tina Vilsbøll, MD, DMSc

Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Novo Nordisk